ARPA-H to Provide Every Cure up to $76 Million for AI-Drive Drug Repurposing

Rare Daily Staff

The Advanced Research Projects Agency for Health (ARPA-H) will provide up to $76 million in funding over three years to Every Cure, to advance AI-identified drug candidates into preclinical and clinical testing.

Every Cure is a nonprofit focused on repurposing approved drugs to treat new diseases.

The new funding phase will support evaluation of promising therapies discovered by Every Cure’s AI-powered MATRIX platform, which analyzes biomedical data to identify new disease applications for existing FDA-approved drugs.

“This next phase will allow us to do the essential work of evaluating these potentially life-saving treatments in the lab and clinical trials, accelerating access to potential treatments for those who urgently need them,” said David Fajgenbaum, Every Cure’s co-founder and president.

Building on an earlier $48.3 million award from ARPA-H that supported development of the MATRIX platform, the new agreement will fund preclinical studies of at least 20 high-priority drug repurposing opportunities, and clinical trials for 10 of the most promising programs.

Every Cure’s current portfolio includes candidates across a range of diseases, from ultra-rare conditions such as Bachmann-Bupp syndrome—which has been identified in about 20 patients worldwide—to more common illnesses, including breast cancer.

“Drug repurposing at this scale represents a fundamentally different way of approaching unmet medical need,” said Scott Gorman, ARPA-H program manager for MATRIX. “By combining artificial intelligence with rigorous preclinical and clinical validation, MATRIX is advancing a model that could dramatically expand treatment options for both rare and common diseases.”